BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo G, Xu W, Zhao Y, Jin S, Wang S, Liu Q, Chen X, Wang J, Dong F, Hu DN, Reinach PS, Yan D. RNA m6 A methylation regulates uveal melanoma cell proliferation, migration, and invasion by targeting c-Met. J Cell Physiol 2020;235:7107-19. [PMID: 32017066 DOI: 10.1002/jcp.29608] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Sutopo NC, Kim JH, Cho JY. Role of histone methylation in skin cancers: Histone methylation-modifying enzymes as a new class of targets for skin cancer treatment. Biochim Biophys Acta Rev Cancer 2023;1878:188865. [PMID: 36841366 DOI: 10.1016/j.bbcan.2023.188865] [Reference Citation Analysis]
2 Ni Y, Zhang H, Chu L, Zhao Y. m6A Modification-Association with Oxidative Stress and Implications on Eye Diseases. Antioxidants (Basel) 2023;12. [PMID: 36830067 DOI: 10.3390/antiox12020510] [Reference Citation Analysis]
3 Ran Y, Yan Z, Jiang B, Liang P. N6-methyladenosine functions and its role in skin cancer. Exp Dermatol 2023;32:4-12. [PMID: 36314059 DOI: 10.1111/exd.14696] [Reference Citation Analysis]
4 Shi HZ, Xiong JS, Gan L, Zhang Y, Zhang CC, Kong YQ, Miao QJ, Tian CC, Li R, Liu JQ, Zhang EJ, Bu WB, Wang Y, Cheng XF, Sun JF, Chen H. N6-methyladenosine reader YTHDF3 regulates melanoma metastasis via its 'executor'LOXL3. Clin Transl Med 2022;12:e1075. [PMID: 36324258 DOI: 10.1002/ctm2.1075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chen X, Tong X, Zhou L, Huang J, Gao L, Zeng J, Tan L. Critical role of m6A modification in T-helper cell disorders. Mol Immunol 2022;151:1-10. [PMID: 36058047 DOI: 10.1016/j.molimm.2022.08.015] [Reference Citation Analysis]
6 You Y, Wen D, Zeng L, Lu J, Xiao X, Chen Y, Song H, Liu Z. ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression. Int J Biol Sci 2022;18:5001-18. [PMID: 35982895 DOI: 10.7150/ijbs.70149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Du Q, Huo F, Du W, Sun X, Jiang X, Zhang L, Pei D. METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA. Oncogene. [DOI: 10.1038/s41388-022-02435-2] [Reference Citation Analysis]
8 Wang T, Bai J, Zhang Y, Xue Y, Peng Q. N6-Methyladenosine regulator RBM15B acts as an independent prognostic biomarker and its clinical significance in uveal melanoma. Front Immunol 2022;13:918522. [DOI: 10.3389/fimmu.2022.918522] [Reference Citation Analysis]
9 Hu C, Liu J, Li Y, Jiang W, Ji D, Liu W, Ma T. Multifaceted Roles of the N6-Methyladenosine RNA Methyltransferase METTL3 in Cancer and Immune Microenvironment. Biomolecules 2022;12:1042. [DOI: 10.3390/biom12081042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang F, Liu H, Duan M, Wang G, Zhang Z, Wang Y, Qian Y, Yang Z, Jiang X. Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application. J Hematol Oncol 2022;15. [DOI: 10.1186/s13045-022-01304-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Luo G, Xu W, Chen X, Wang S, Wang J, Dong F, Hu DN, Reinach PS, Yan D. NSUN2-mediated RNA m5C modification modulates uveal melanoma cell proliferation and migration. Epigenetics 2022;:1-12. [PMID: 35757999 DOI: 10.1080/15592294.2022.2088047] [Reference Citation Analysis]
12 Chen Y, Yi X, Sun N, Guo W, Li C. Epigenetics Regulates Antitumor Immunity in Melanoma. Front Immunol 2022;13:868786. [PMID: 35693795 DOI: 10.3389/fimmu.2022.868786] [Reference Citation Analysis]
13 Li X, Ma B, Zhang W, Song Z, Zhang X, Liao M, Li X, Zhao X, Du M, Yu J, He S, Yan H. The essential role of N6-methyladenosine RNA methylation in complex eye diseases. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.05.008] [Reference Citation Analysis]
14 Xue C, Chu Q, Zheng Q, Jiang S, Bao Z, Su Y, Lu J, Li L. Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine. Signal Transduct Target Ther 2022;7:142. [PMID: 35484099 DOI: 10.1038/s41392-022-01003-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
15 Wilkinson E, Cui YH, He YY. Roles of RNA Modifications in Diverse Cellular Functions. Front Cell Dev Biol 2022;10:828683. [PMID: 35350378 DOI: 10.3389/fcell.2022.828683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Xu P, Ge R. Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy. European Journal of Medicinal Chemistry 2022;230:114118. [DOI: 10.1016/j.ejmech.2022.114118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Yue Z, Cao M, Hong A, Zhang Q, Zhang G, Jin Z, Zhao L, Wang Q, Fang F, Wang Y, Sun J. m6A Methyltransferase METTL3 Promotes the Progression of Primary Acral Melanoma via Mediating TXNDC5 Methylation. Front Oncol 2022;11:770325. [DOI: 10.3389/fonc.2021.770325] [Reference Citation Analysis]
18 Chen P, Hu J, Han X, Chen Y. Advances in the functional roles of N6-methyladenosine modification in cancer progression: mechanisms and clinical implications. Mol Biol Rep 2022. [PMID: 35025029 DOI: 10.1007/s11033-022-07126-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Wang N, Yao F, Liu D, Jiang H, Xia X, Xiong S. RNA N6-methyladenosine in nonocular and ocular disease. J Cell Physiol 2021. [PMID: 34913163 DOI: 10.1002/jcp.30652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Wu L, Hu X, Dai H, Chen K, Liu B. Identification of an m6A Regulators-Mediated Prognosis Signature For Survival Prediction and Its Relevance to Immune Infiltration in Melanoma. Front Cell Dev Biol 2021;9:718912. [PMID: 34900983 DOI: 10.3389/fcell.2021.718912] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhang X, Liu P, Zheng X, Wang J, Peng Q, Li Z, Wei L, Liu C, Wu Y, Wen Y, Yan Q, Ma J. N6-methyladenosine regulates ATM expression and downstream signaling. J Cancer 2021;12:7041-51. [PMID: 34729106 DOI: 10.7150/jca.64061] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Gao JF, Zhang L. The role of N6-methyladenosine (m6A) in eye diseases. Mol Biol Rep 2021. [PMID: 34331665 DOI: 10.1007/s11033-021-06596-3] [Reference Citation Analysis]
23 Liu Z, Li S, Huang S, Wang T, Liu Z. N6-Methyladenosine Regulators and Related LncRNAs Are Potential to be Prognostic Markers for Uveal Melanoma and Indicators of Tumor Microenvironment Remodeling. Front Oncol 2021;11:704543. [PMID: 34395276 DOI: 10.3389/fonc.2021.704543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Feng ZY, Wang T, Su X, Guo S. Identification of the m6A RNA Methylation Regulators WTAP as a Novel Prognostic Biomarker and Genomic Alterations in Cutaneous Melanoma. Front Mol Biosci 2021;8:665222. [PMID: 34291082 DOI: 10.3389/fmolb.2021.665222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
25 Gu Y, Wu X, Zhang J, Fang Y, Pan Y, Shu Y, Ma P. The evolving landscape of N6-methyladenosine modification in the tumor microenvironment. Mol Ther 2021;29:1703-15. [PMID: 33839323 DOI: 10.1016/j.ymthe.2021.04.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 14.0] [Reference Citation Analysis]
26 Zhang X, Zhong L, Zou Z, Liang G, Tang Z, Li K, Tan S, Huang Y, Zhu X. Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases. Front Oncol 2021;11:623170. [PMID: 33816257 DOI: 10.3389/fonc.2021.623170] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
27 He F, Yu J, Yang J, Wang S, Zhuang A, Shi H, Gu X, Xu X, Chai P, Jia R. m6A RNA hypermethylation-induced BACE2 boosts intracellular calcium release and accelerates tumorigenesis of ocular melanoma. Mol Ther 2021;29:2121-33. [PMID: 33601055 DOI: 10.1016/j.ymthe.2021.02.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
28 Nombela P, Miguel-López B, Blanco S. The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer 2021;20:18. [PMID: 33461542 DOI: 10.1186/s12943-020-01263-w] [Cited by in Crossref: 93] [Cited by in F6Publishing: 100] [Article Influence: 46.5] [Reference Citation Analysis]
29 Hao L, Yin J, Yang H, Li C, Zhu L, Liu L, Zhong J. ALKBH5-mediated m6A demethylation of FOXM1 mRNA promotes progression of uveal melanoma. Aging (Albany NY) 2021;13:4045-62. [PMID: 33428593 DOI: 10.18632/aging.202371] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
30 Li B, Jiang J, Assaraf YG, Xiao H, Chen Z, Huang C. Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. Drug Resistance Updates 2020;53:100720. [DOI: 10.1016/j.drup.2020.100720] [Cited by in Crossref: 57] [Cited by in F6Publishing: 62] [Article Influence: 19.0] [Reference Citation Analysis]
31 Wen K, Zhang Y, Li Y, Wang Q, Sun J. Comprehensive analysis of transcriptome-wide m6A methylome in the anterior capsule of the lens of high myopia patients. Epigenetics 2021;16:955-68. [PMID: 33108260 DOI: 10.1080/15592294.2020.1834917] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
32 Hu J, Lin Y. Fusarium infection alters the m6A-modified transcript landscape in the cornea. Exp Eye Res 2020;200:108216. [PMID: 32890482 DOI: 10.1016/j.exer.2020.108216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
33 Zeng C, Huang W, Li Y, Weng H. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol 2020;13:117. [PMID: 32854717 DOI: 10.1186/s13045-020-00951-w] [Cited by in Crossref: 95] [Cited by in F6Publishing: 103] [Article Influence: 31.7] [Reference Citation Analysis]
34 Li T, Gu M, Deng A, Qian C. Increased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: a systematic analysis. Cancer Cell Int 2020;20:239. [PMID: 32549786 DOI: 10.1186/s12935-020-01309-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
35 Liu S, Li Q, Chen K, Zhang Q, Li G, Zhuo L, Zhai B, Sui X, Hu X, Xie T. The emerging molecular mechanism of m6A modulators in tumorigenesis and cancer progression. Biomed Pharmacother 2020;127:110098. [PMID: 32299028 DOI: 10.1016/j.biopha.2020.110098] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]